Silver Book Fact

Anti-platelet therapy stroke risk reduction

Anti-platelet therapy after a stroke or TIA reduces the risk of nonfatal ischemic strokes by 28% and fatal strokes by 16%.

Antithrombotic Trialists' Collaboration. Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients. BMJ. 2002; 324(7329): 71-86. http://www.bmj.com/content/324/7329/71.full

Reference

Title
Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients
Publication
BMJ
Publication Date
2002
Authors
Antithrombotic Trialists' Collaboration
Volume & Issue
Volume 324, Issue 7329
Pages
71-86
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • It is estimated that the number of quality-adjusted life-years achieved with each $1 million spent on antihypertensive drug therapy is between 20-50 to more than 200.  
  • Between 1980 and 2000, stroke mortality rates fell from 96.2 to 60.8 per 100,000 persons.  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • Several prevention/early detection interventions for cardiovascular disease have cost-effectiveness ratios of $50,000-$70,000 per life saved.  
  • Aspirin use in AFib patients
    Meta-analysis of a number of randomized controlled trials found that aspirin use in atrial fibrillation patients reduced stroke risk by an average 22%.